Tadashi Manabe, MD, PhD
Postdoctoral Scholar
Medicine
School of Medicine
After receiving my medical degree in 2012, I specialized in pulmonary medicine and practiced as a respiratory physician. Over nine years of practice, I was the attending physician for patients with acute and chronic respiratory diseases ranging from COVID-19 to lung cancer.
Show full bio (140 words) Hide full bio
I garnered a keen interest in the management of lung cancer because of the poor outcomes of my patients with current therapies; the summation of my clinical experiences inspired me to pursue basic research to develop new cancer treatments for my future patients.
In 2017, I entered the Keio University Graduate school of Medicine. During my graduate training, I elucidated a novel resistance mechanism of a third-generation EGFR-tyrosine kinase inhibitor osimertinib, the first-line treatment for EGFR mutation-positive non-small-cell lung cancer (Mol Cancer Res, 2020). Upon completing my Ph.D., I aspired to study in the U.S., believing it would provide me with in-depth knowledge of cancer biology, broad perspectives, various experiences, and many personal connections. Having considered the above, I was fortunate to begin my postdoctoral fellowship at UCSF in April 2021.
Awards
Show all (2) Hide
- Damon Runyon Fellowship Award, Damon Runyon Cancer Research Foundation, 2022
- Education Award, Best Fellows Oral Abstract Session, International Association for the Study of Lung Cancer (IASLC), 2022
Education & Training
Show all (4) Hide
- Ph.D. Keio University Graduate School of Medicine 09/2020
- Clinical Fellow Pulmonary Medicine Keio University School of Medicine 03/2020
- Residency Internal Medicine Keio University School of Medicine 03/2016
- M.D. Keio University School of Medicine 03/2012
Interests
Show all (4) Hide
- Establishment of patient-derived cancer models
- Developing new targeted therapies
- MAPK signaling in lung cancer
- Drug resistance mechanisms in lung cancer
Websites
Show all (2) Hide
- researchmap (researchmap.jp)
- Google Scholar (scholar.google.co.jp)
Grants and Projects
Show all (4) Hide
- , Damon Runyon Cancer Research Foundation, Fellowship Award, 2022
- , Uehara Memorial Foundation, Overseas Research Fellowships, 2021-2022
- , Japan Society for the Promotion of Science, Research Fellowships for Young Scientists (DC2), 2019-2021
- , Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), 2017-2019
Publications (16)
Top publication keywords:
AcrylamidesAcetonitrilesMice, Inbred NODGuanine Nucleotide Exchange FactorsCarcinoma, Non-Small-Cell LungReceptor, IGF Type 1Genes, erbB-1GTPase-Activating ProteinsCetuximabFibroblast Growth Factor 9Proto-Oncogene Proteins p21(ras)Lung NeoplasmsJapanInsulin-Like Growth Factor IIAniline Compounds
-
Cluster analysis of long COVID in Japan and association of its trajectory of symptoms and quality of life.
BMJ open respiratory research 2024 Ito F, Terai H, Kondo M, Takemura R, Namkoong H, Asakura T, Chubachi S, Masuzawa K, Nakayama S, Suzuki Y, Hashiguchi M, Kagyo J, Shiomi T, Minematsu N, Manabe T, Fukui T, Funatsu Y, Koh H, Masaki K, … -
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nature genetics 2023 Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, Angelova M, Gini B, … -
Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study.
Respiratory investigation 2023 Terai H, Ishii M, Takemura R, Namkoong H, Shimamoto K, Masaki K, Tanosaki T, Chubachi S, Matsuyama E, Hayashi R, Shimada T, Shigematsu L, Ito F, Kaji M, Takaoka H, Kurihara M, Nakagawara K, Tomiyasu S… -
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force.
Nature communications 2022 Wang QS, Edahiro R, Namkoong H, Hasegawa T, Shirai Y, Sonehara K, Tanaka H, Lee H, Saiki R, Hyugaji T, Shimizu E, Katayama K, Kanai M, Naito T, Sasa N, Yamamoto K, Kato Y, Morita T, Takahashi K, … -
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Nature 2022 Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, …
Show all (11 more) Hide
-
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
The Journal of clinical investigation 2022 Manabe T, Bivona TG -
Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol.
BMJ open respiratory research 2021 Nakagawara K, Namkoong H, Terai H, Masaki K, Tanosaki T, Shimamoto K, Lee H, Tanaka H, Okamori S, Kabata H, Chubachi S, Ikemura S, Kamata H, Yasuda H, Kawada I, Ishii M, Ishibashi Y, Harada S, Fujita … -
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer.
Cancer research 2021 Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, … -
Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
Biochemical and biophysical research communications 2020 Kobayashi K, Terai H, Yasuda H, Hamamoto J, Hayashi Y, Takeuchi O, Mitsuishi Y, Masuzawa K, Manabe T, Ikemura S, Kawada I, Suzuki Y, Soejima K, Fukunaga K -
SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells.
Molecular cancer research : MCR 2020 Terai H, Hamamoto J, Emoto K, Masuda T, Manabe T, Kuronuma S, Kobayashi K, Masuzawa K, Ikemura S, Nakayama S, Kawada I, Suzuki Y, Takeuchi O, Suzuki Y, Ohtsuki S, Yasuda H, Soejima K, Fukunaga K -
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Journal for immunotherapy of cancer 2020 Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, … -
IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.
Molecular cancer research : MCR 2020 Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, Kobayashi K, Masuzawa K, Ikemura S, Kawada I, Hayashi Y, Fukui K, Horimoto K, Fukunaga K, Soejima K -
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
Molecular cancer therapeutics 2019 Oashi A, Yasuda H, Kobayashi K, Tani T, Hamamoto J, Masuzawa K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K -
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
Proceedings of the National Academy of Sciences of the United States of America 2019 Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, … -
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Lung cancer (Amsterdam, Netherlands) 2018 Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K -
Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.
OncoTargets and therapy 2018 Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T